JPMorgan Chase & Co. Begins Coverage on Vor Biopharma (NASDAQ:VOR)

Equities researchers at JPMorgan Chase & Co. started coverage on shares of Vor Biopharma (NASDAQ:VOR) in a report issued on Tuesday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $43.00 price target on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 316.26% from the stock’s current price.

A number of other research analysts have also issued reports on the company. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. HC Wainwright lowered their price objective on shares of Vor Biopharma from $55.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a report on Wednesday, September 24th. Finally, Robert W. Baird upgraded shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $20.00 to $64.00 in a report on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $68.86.

Vor Biopharma Trading Down 3.6%

Shares of VOR stock opened at $10.33 on Tuesday. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80. The firm’s fifty day moving average price is $19.42. The firm has a market cap of $107.54 million, a PE ratio of -0.03 and a beta of 2.08.

Insider Transactions at Vor Biopharma

In other news, Director Ra Capital Management, L.P. sold 24,579 shares of the business’s stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $25.12, for a total transaction of $617,424.48. Following the sale, the director owned 779,652 shares in the company, valued at $19,584,858.24. The trade was a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $30.05, for a total transaction of $349,060.80. Following the completion of the sale, the insider owned 1,167,109 shares of the company’s stock, valued at approximately $35,071,625.45. This trade represents a 0.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 2,179,441 shares of company stock valued at $52,075,549 over the last ninety days. Insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

Several large investors have recently added to or reduced their stakes in VOR. Squarepoint Ops LLC purchased a new stake in shares of Vor Biopharma in the third quarter valued at $230,000. Bank of America Corp DE raised its position in Vor Biopharma by 679.3% during the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after buying an additional 4,144 shares during the period. BNP Paribas Financial Markets raised its position in Vor Biopharma by 497.3% during the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after buying an additional 5,058 shares during the period. Bridgeway Capital Management LLC purchased a new stake in Vor Biopharma in the 3rd quarter worth about $304,000. Finally, Polymer Capital Management HK LTD purchased a new stake in Vor Biopharma in the 3rd quarter worth about $1,035,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.